Last reviewed · How we verify
NCT05000853: IRON-PATH II
New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure
trial testing Iron Carboxymaltose in Heart Failure in 210 participants. Status unknown.
1 July 2023
Quick facts
| Lead sponsor | Hospital Universitari de Bellvitge |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 210 |
| Start date | 1 August 2021 |
| Primary completion | 1 July 2023 |
| Estimated completion | 1 August 2023 |
| Sites | 2 locations across Spain |
Drugs / interventions tested
- Iron Carboxymaltose — full drug profile →
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Hospital Universitari de Bellvitge
Who can join
18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of our study is to understand the biological pathways involved in the occurrence of IDy in patients with HF since ID is very common and supposes a negative impact in terms of clinical outcomes in these patients. In this context, a deeper understanding of the mechanisms involved in the development of ID in these patients and the impact on the altered biological pathways after iron replenishment will pave the way for an improvement and simplification of the preventive strategies in patients with HF.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting Inflammation and Iron Deficiency in Heart Failure: A Focus on Older Adults.
Maidana D, Arroyo-Álvarez A, Barreres-Martín G, Arenas-Loriente A, et al · · 2025 · cited 7× · PMID 40002874 · DOI 10.3390/biomedicines13020462 -
Myocardial Performance Improvement After Iron Replacement in Heart Failure Patients: The IRON-PATH II Echo-Substudy.
Ramos-Polo R, Ras-Jiménez MDM, Basalo Carbajales MDC, Jovells-Vaqué S, et al · · 2025 · cited 2× · PMID 40565791 · DOI 10.3390/jcm14124048 -
Serum Growth Differentiation Factor 15 (GDF15) Levels Reflect Ischemic Etiology in Heart Failure Patients with Iron Deficiency: A Cross-Sectional Study.
Tajes M, Ras-Jiménez MDM, Girona J, Ramos-Polo R, et al · · 2025 · PMID 41008541 · DOI 10.3390/biom15091234
Verify or expand the search:
- PubMed search for NCT05000853
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Iron Carboxymaltose
Trials testing the same drug.
- NCT07384663 — EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY · Phase 1 · completed
- NCT06434025 — IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency · Phase 3 · not yet recruiting
- NCT06911034 — Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women · Phase 4 · completed
- NCT03957057 — Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia · Phase 3 · completed
- NCT04475887 — Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation · Phase 4 · unknown
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Hospital Universitari de Bellvitge trials
Trials by the same sponsor.
- NCT07522931 — Morphometric Study of the Female Pelvic and Lower Abdominal Retroperitoneum in Cadavers · recruiting
- NCT07155590 — Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia · active not recruiting
- NCT06653192 — EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial) · NA · recruiting
- NCT07178483 — Evaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure · active not recruiting
- NCT06955221 — Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05000853 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari de Bellvitge
- Last refreshed: 13 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05000853.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing